- Earlier this week, AXT highlighted that tight supply and rising demand for indium phosphide (InP), a critical material for AI lasers, have already pushed InP substrate prices higher in the first half of the year, with industry expectations for further increases as the AI buildout continues.
- The company’s newly secured supply deals with Lumentum Holdings and Coherent Corp., alongside its InP capacity expansion, underline its growing role in supplying key materials to AI and high-speed connectivity applications amid ongoing export challenges.
- Against this backdrop of tightening InP supply and new customer agreements, we’ll examine how the capacity expansion reshapes AXT’s existing investment narrative.
AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
AXT Investment Narrative Recap
To own AXT, you need to believe that compound semiconductor substrates, especially indium phosphide for AI and high speed optics, remain central to future connectivity, and that AXT can translate that role into durable profitability despite export and customer concentration risks. The latest InP price spike and capacity deals may boost the near term demand catalyst, but they do not remove the biggest overhang: ongoing export permit uncertainty and exposure to shifting China related regulations.
Among recent announcements, the long term supply and capacity reservation agreement with Lumentum stands out in light of this InP news. It secures multi year volume commitments and sizable deposits tied to indium phosphide wafers, directly reinforcing the thesis that AI driven optical demand can support higher utilization and revenue. At the same time, it intensifies AXT’s dependence on a small set of large customers, which could amplify revenue volatility if order patterns change.
Yet investors should be aware that export restrictions and regulatory shifts in China could still...
Read the full narrative on AXT (it's free!)
AXT's narrative projects $374.9 million revenue and $141.0 million earnings by 2029. This requires 57.5% yearly revenue growth and about a $155.3 million earnings increase from -$14.3 million today.
Uncover how AXT's forecasts yield a $96.50 fair value, in line with its current price.
Exploring Other Perspectives
Some of the most optimistic analysts already expected revenue to reach about US$511,200,000 by 2029, and this InP price shock could either reinforce that enthusiasm or highlight how much those forecasts depend on export permits remaining manageable and demand for AXT’s materials not being diverted to alternative substrates.
Explore 5 other fair value estimates on AXT - why the stock might be worth as much as 30% more than the current price!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your AXT research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free AXT research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AXT's overall financial health at a glance.
Ready For A Different Approach?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- Find 53 companies with promising cash flow potential yet trading below their fair value.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com